Stockreport

Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD Sep. 27, 2024 1:16 PM ET By: Dulan Lokuwithana , SA News Editor [Seeking Alpha]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF FDA approved a label expansion for its asthma therapy Dupixent (dupilumab) for certain patients with chronic obstructive pulmonary disease (COPD), a respiratory disorder [Read more]